News >

Post-Ibrutinib Treatments Show Promise in CLL

Gina Columbus @ginacolumbusonc
Published: Wednesday, May 08, 2019

Sameem Abedin, MD

Sameem Abedin, MD

While long-term data have solidified the frontline role of ibrutinib (Imbruvica) in the chronic lymphocytic leukemia (CLL) paradigm for several patients, venetoclax (Venclexta), duvelisib (Copiktra), and acalabrutinib (Calquence) could be beneficial for those who fail on or are unable to tolerate the FDA-approved BTK inhibitor, explained Sameem Abedin, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication